GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Goodwill

Albany Molecular Research (Albany Molecular Research) Goodwill : $238.7 Mil (As of Jun. 2017)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Albany Molecular Research's goodwill for the quarter that ended in Jun. 2017 was $238.7 Mil.


Albany Molecular Research Goodwill Historical Data

The historical data trend for Albany Molecular Research's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Goodwill Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 61.78 169.47 231.26

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.70 241.40 231.26 230.89 238.70

Albany Molecular Research Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Albany Molecular Research  (NAS:AMRI) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Albany Molecular Research's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Goodwill-to-Asset (A: Dec. 2016 )=Goodwill/Total Assets
=231.26/1209.648
=0.19

Albany Molecular Research's Goodwill-to-Asset Ratio for the quarter that ended in Jun. 2017 is calculated as

Goodwill-to-Asset (Q: Jun. 2017 )=Goodwill/Total Assets
=238.7/1242.374
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Albany Molecular Research Goodwill Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines